STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe

M. Grehn; S. Mandija; M. Miszczyk; D. Krug; B. Tomasik; K.E. Stickney; P. Alcantara; F. Alongi; M. Anselmino; R.S. Aranda; B.V. Balgobind; J. Boda-Heggemann; L.H. Boldt; N. Bottoni; J. Cvek; O. Elicin; G.M. De Ferrari; R.J. Hassink; C. Hazelaar; G. Hindricks; C. Hurkmans; C. Iotti; T. Jadczyk; O. Jiravsky; R. Jumeau; S.B. Kristiansen; M. Levis; M.A. Lopez; J. Marti-Almor; F. Mehrhof; D.S. Moller; G. Molon; A. Ouss; P. Peichl; J. Plasek; P.G. Postema; A. Quesada; T. Reichlin; R. Rordorf; B. Rudic; A.M. Saguner; R.M.A. ter Bekke; J.L. Torrecilla; E.G.C. Troost; V. Vitolo; N. Andratschke; K. Zeppenfeld; S. Blamek; M. Fast; L. de Panfilis; J. Verhoeff

doi:10.1093/europace/euac238

STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe

M. Grehn, S. Mandija, M. Miszczyk, D. Krug, B. Tomasik, K.E. Stickney, P. Alcantara, F. Alongi, M. Anselmino, R.S. Aranda, B.V. Balgobind, J. Boda-Heggemann, L.H. Boldt, N. Bottoni, J. Cvek, O. Elicin, G.M. De Ferrari, R.J. Hassink, C. Hazelaar, G. HindricksC. Hurkmans, C. Iotti, T. Jadczyk, O. Jiravsky, R. Jumeau, S.B. Kristiansen, M. Levis, M.A. Lopez, J. Marti-Almor, F. Mehrhof, D.S. Moller, G. Molon, A. Ouss, P. Peichl, J. Plasek, P.G. Postema, A. Quesada, T. Reichlin, R. Rordorf, B. Rudic, A.M. Saguner, R.M.A. ter Bekke, J.L. Torrecilla, E.G.C. Troost, V. Vitolo, N. Andratschke, K. Zeppenfeld, S. Blamek, M. Fast, L. de Panfilis, J. Verhoeff^*

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions' experience in VT catheter ablation (83% >= 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.

Original language	English
Pages (from-to)	1284-1295
Number of pages	12
Journal	EP Europace
Volume	25
Issue number	4
Early online date	1 Mar 2023
DOIs	https://doi.org/10.1093/europace/euac238
Publication status	Published - 15 Apr 2023

Keywords

Stereotactic arrhythmia radioablation
Ventricular tachycardia
Cardiac arrhythmias
Stereotactic body radiotherapy
Consortium
EU Horizon 2020
STRUCTURAL HEART-DISEASE
RADIATION-THERAPY
VENTRICULAR-TACHYCARDIA
CONTOURING ATLAS
CATHETER ABLATION
BODY RADIOTHERAPY
DELINEATION
GUIDELINES

Access to Document

10.1093/europace/euac238Licence: CC BY-NC

Cite this

Grehn, M., Mandija, S., Miszczyk, M., Krug, D., Tomasik, B., Stickney, K. E., Alcantara, P., Alongi, F., Anselmino, M., Aranda, R. S., Balgobind, B. V., Boda-Heggemann, J., Boldt, L. H., Bottoni, N., Cvek, J., Elicin, O., De Ferrari, G. M., Hassink, R. J., Hazelaar, C., ... Verhoeff, J. (2023). STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe. EP Europace, 25(4), 1284-1295. https://doi.org/10.1093/europace/euac238

@article{2b6c7be8d84442558849e4313cd65d79,

title = "STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe",

abstract = "The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions' experience in VT catheter ablation (83% >= 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.",

keywords = "Stereotactic arrhythmia radioablation, Ventricular tachycardia, Cardiac arrhythmias, Stereotactic body radiotherapy, Consortium, EU Horizon 2020, STRUCTURAL HEART-DISEASE, RADIATION-THERAPY, VENTRICULAR-TACHYCARDIA, CONTOURING ATLAS, CATHETER ABLATION, BODY RADIOTHERAPY, DELINEATION, GUIDELINES",

author = "M. Grehn and S. Mandija and M. Miszczyk and D. Krug and B. Tomasik and K.E. Stickney and P. Alcantara and F. Alongi and M. Anselmino and R.S. Aranda and B.V. Balgobind and J. Boda-Heggemann and L.H. Boldt and N. Bottoni and J. Cvek and O. Elicin and {De Ferrari}, G.M. and R.J. Hassink and C. Hazelaar and G. Hindricks and C. Hurkmans and C. Iotti and T. Jadczyk and O. Jiravsky and R. Jumeau and S.B. Kristiansen and M. Levis and M.A. Lopez and J. Marti-Almor and F. Mehrhof and D.S. Moller and G. Molon and A. Ouss and P. Peichl and J. Plasek and P.G. Postema and A. Quesada and T. Reichlin and R. Rordorf and B. Rudic and A.M. Saguner and {ter Bekke}, R.M.A. and J.L. Torrecilla and E.G.C. Troost and V. Vitolo and N. Andratschke and K. Zeppenfeld and S. Blamek and M. Fast and {de Panfilis}, L. and J. Verhoeff",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. ",

year = "2023",

month = apr,

day = "15",

doi = "10.1093/europace/euac238",

language = "English",

volume = "25",

pages = "1284--1295",

journal = "EP Europace",

issn = "1099-5129",

publisher = "Oxford University Press",

number = "4",

}

Grehn, M, Mandija, S, Miszczyk, M, Krug, D, Tomasik, B, Stickney, KE, Alcantara, P, Alongi, F, Anselmino, M, Aranda, RS, Balgobind, BV, Boda-Heggemann, J, Boldt, LH, Bottoni, N, Cvek, J, Elicin, O, De Ferrari, GM, Hassink, RJ, Hazelaar, C, Hindricks, G, Hurkmans, C, Iotti, C, Jadczyk, T, Jiravsky, O, Jumeau, R, Kristiansen, SB, Levis, M, Lopez, MA, Marti-Almor, J, Mehrhof, F, Moller, DS, Molon, G, Ouss, A, Peichl, P, Plasek, J, Postema, PG, Quesada, A, Reichlin, T, Rordorf, R, Rudic, B, Saguner, AM, ter Bekke, RMA, Torrecilla, JL, Troost, EGC, Vitolo, V, Andratschke, N, Zeppenfeld, K, Blamek, S, Fast, M, de Panfilis, L & Verhoeff, J 2023, 'STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe', EP Europace, vol. 25, no. 4, pp. 1284-1295. https://doi.org/10.1093/europace/euac238

STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe. / Grehn, M.; Mandija, S.; Miszczyk, M. et al.
In: EP Europace, Vol. 25, No. 4, 15.04.2023, p. 1284-1295.

Research output: Contribution to journal › (Systematic) Review article › peer-review

TY - JOUR

T1 - STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe

AU - Grehn, M.

AU - Mandija, S.

AU - Miszczyk, M.

AU - Krug, D.

AU - Tomasik, B.

AU - Stickney, K.E.

AU - Alcantara, P.

AU - Alongi, F.

AU - Anselmino, M.

AU - Aranda, R.S.

AU - Balgobind, B.V.

AU - Boda-Heggemann, J.

AU - Boldt, L.H.

AU - Bottoni, N.

AU - Cvek, J.

AU - Elicin, O.

AU - De Ferrari, G.M.

AU - Hassink, R.J.

AU - Hazelaar, C.

AU - Hindricks, G.

AU - Hurkmans, C.

AU - Iotti, C.

AU - Jadczyk, T.

AU - Jiravsky, O.

AU - Jumeau, R.

AU - Kristiansen, S.B.

AU - Levis, M.

AU - Lopez, M.A.

AU - Marti-Almor, J.

AU - Mehrhof, F.

AU - Moller, D.S.

AU - Molon, G.

AU - Ouss, A.

AU - Peichl, P.

AU - Plasek, J.

AU - Postema, P.G.

AU - Quesada, A.

AU - Reichlin, T.

AU - Rordorf, R.

AU - Rudic, B.

AU - Saguner, A.M.

AU - ter Bekke, R.M.A.

AU - Torrecilla, J.L.

AU - Troost, E.G.C.

AU - Vitolo, V.

AU - Andratschke, N.

AU - Zeppenfeld, K.

AU - Blamek, S.

AU - Fast, M.

AU - de Panfilis, L.

AU - Verhoeff, J.

PY - 2023/4/15

Y1 - 2023/4/15

N2 - The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions' experience in VT catheter ablation (83% >= 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.

AB - The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions' experience in VT catheter ablation (83% >= 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.

KW - Stereotactic arrhythmia radioablation

KW - Ventricular tachycardia

KW - Cardiac arrhythmias

KW - Stereotactic body radiotherapy

KW - Consortium

KW - EU Horizon 2020

KW - STRUCTURAL HEART-DISEASE

KW - RADIATION-THERAPY

KW - VENTRICULAR-TACHYCARDIA

KW - CONTOURING ATLAS

KW - CATHETER ABLATION

KW - BODY RADIOTHERAPY

KW - DELINEATION

KW - GUIDELINES

U2 - 10.1093/europace/euac238

DO - 10.1093/europace/euac238

M3 - (Systematic) Review article

C2 - 36879464

SN - 1099-5129

VL - 25

SP - 1284

EP - 1295

JO - EP Europace

JF - EP Europace

IS - 4

ER -

Grehn M, Mandija S, Miszczyk M, Krug D, Tomasik B, Stickney KE et al. STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe. EP Europace. 2023 Apr 15;25(4):1284-1295. Epub 2023 Mar 1. doi: 10.1093/europace/euac238